The Translational Genomics Research Institute (TGen), a branch of the City of Hope, is partnering with a firm from Silicon Valley to become one of the world’s first research institutes to use new artificial intelligence-based detection and sorting technology for classification and isolation. individual diseased cells.
The TGen Research Group on Scientific Technology Assessment (START) is collaborating with Deepcell of Menlo Park, which has developed a new imaging platform that uses AI to analyze individual living cells in real time.
TGen is the first of several agencies to join the Deepcell Access Technology program.
The technology uses cell imaging and AI to analyze the morphology of individual cells -; essentially what it looks like -; in the context of other cells in the sample. This allows users looking for new ways to understand cell biology to characterize and isolate cells from small visual features. Its resolution is powerful enough to see many components of each cell, including the cell nucleus containing its DNA and other genomic information.
Deepcell technology will help our TGen researchers focus on the most critical parts of the cell to gain a deeper understanding of what causes the disease, ”he said.
Stephanie Pond, PhD, TGen Vice President of New Technologies and Head of START
First focus: melanoma
Although Deepcell technology can be used to assess any disease, the TGen-Deepcell partnership will begin with a pilot study to characterize melanoma, one of the most dangerous types of skin cancer. Deepcell previously announced a partnership to study melanoma with the University of Zurich, Switzerland, one of several institutions around the world, along with TGen, that have access to Deepcell technology.
Dr. Jeffrey Trent, President and Director of TGen Research, is leading TGen’s research efforts in the field of melanoma. Decades of genomic research and cell models of both pre-malignant and highly metastatic melanoma have benefited this partnership.
“Great advances in medicine are taking place with the introduction of sharper tools and advanced techniques that can open new avenues for research,” Dr. Trent said. “Deepcell technology undoubtedly opens up new opportunities for us to explore.”
Deepcell provides advanced analysis
“Our unique artificial intelligence technology is transforming cell morphology into a high-bandwidth quantitative marker for use in research,” said Madison Masaeli, co-founder and CEO of Deepcell. “With our technology, scientists can now characterize, identify and isolate viable unlabeled cells, as well as use arrogant AI-derived markers and sorted cells to both complement existing molecular workflows and for a new stand-alone method.”
Dr Pond said that because sorting Deepcell keeps cells intact, it will work hand in hand with established TGen single cell sequencing technology to provide the best possible understanding of how each cell can contribute to disease, especially cancer.
“Understanding the full picture of the tumor microenvironment should provide clues as to how best to treat each patient, especially by focusing on what type of immune cells may be present and coexist with cancer cells,” Dr. Pond said.
New START program from TGen
TGen’s START program is a new technology assessment center dedicated to the evaluation of pre-commercial technologies for use in TGen research programs. TGen perfectly applies the new technology to solve the most unpleasant clinical problems. For example, in the last decade, TGen has gained the world’s first access to several technologies that are changing the field of genomics. These include: rapid sequencing of the entire genome, immunological scanning of PepSeq (protein), sequencing of a single cell, and high-throughput editing of the CRISPR genome.
START explores, installs, tests, and then transfers new technologies to TGen and the larger company City of Hope. This process brings new technologies that feed innovative research programs, which in turn feed new efforts to commercialize TGen.
Research Institute of Translational Genomics